logo
Snakebites: When Is It Too Late For Anti-Venom Injection?

Snakebites: When Is It Too Late For Anti-Venom Injection?

News186 hours ago
Last Updated:
If you live in a snake-prone area during monsoon, stay alert. Some snakes are highly venomous, and without quick anti-venom treatment, their bite can be deadly
Cases of snake bites tend to rise during the rainy season because rainwater floods their burrows, forcing snakes to come out. In search of drier shelter, they often move towards houses or hide in nearby trees, plants, or bushes.
India is home to nearly 400 species of snakes, out of which around 60 are venomous. The Russell's viper, Indian cobra, common krait, and saw-scaled viper are considered the most dangerous.
If you live in an area prone to snake sightings during the monsoon, it's important to remain extra cautious. Many snakes are so venomous that without immediate medical intervention, including an anti-venom injection, the bite can be fatal.
In this situation, knowing how soon anti-venom should be administered after a snake bite and how much anti-venom is required becomes important to save lives in critical situations.
In conversation with Dr Dilip Singh, Chief Medical Superintendent at the Government Medical College, Kannauj, Uttar Pradesh, he tried to answer these important questions:
Injection For Snake Bite
Dr Dilip Singh explains that the snake anti-venom injection is a prescription medicine given as treatment for venomous snake bites. It is regarded as the most effective remedy for such cases.
The anti-venom used is a combination designed to counteract the venom of four major types of snakes. It works by neutralising the venom and can save lives even after a bite from a venomous snake.
According to Dr Singh, an anti-venom injection is not needed for non-venomous snake bites. However, in the case of venomous bites, such as those from a cobra or krait, the anti-venom must be administered immediately, ideally within 30 to 40 minutes. If given even earlier, the chances of a faster recovery increase. In some cases, the injection can still be beneficial if administered within 24 hours.
Which Venom Attacks Which Organ?
According to the expert, before administering anti-venom, it is crucial to understand what kind of snake venom is involved and its effect on the body.
Snake venom is broadly categorised into two types: cardiotoxic and neurotoxic. These affect the nervous system and cardiovascular system, respectively. In cardiotoxic cases, symptoms can include heart failure, an increased heart rate, and high or low blood pressure. In neurotoxic cases, patients may experience unconsciousness, fainting, and high-grade fever.
Dose Of Anti-Venom
According to Dr Singh, the required dose of anti-venom depends on the condition of the patient. In some cases, where the effect of the venom is mild, only one dose is needed. In more serious cases, patients may require three or four follow-up doses. If the snake is highly venomous, a larger quantity of anti-venom may be needed, as each dose may contain fewer antibodies.
Types of poison
Neurotoxic Poison: This type of venom affects the nervous system, leading to muscle weakness, paralysis, and even death. Neurotoxin is commonly found in snakes like the cobra, krait, and viper.
Haemotoxic Poison: This venom damages blood vessels, which can lead to bleeding, organ failure, and death. Haemotoxin is usually found in snakes like the Russell's viper, tiger snake, and king cobra.
Cytotoxic Poison: This type of venom destroys body tissues, resulting in swelling, pain, and potentially death. Cytotoxin is usually found in snakes like the rattlesnake, boa constrictor, and python.
Location :
Kannauj, India, India
First Published:
July 28, 2025, 10:28 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics
New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics

Mint

timean hour ago

  • Mint

New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics

Nephrocare Health Services Limited, widely recognized under the brand name NephroPlus, has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to raise ₹353.4 crore through an initial public offering (IPO). The Hyderabad-based company plans to use the proceeds to expand its network of dialysis clinics across India and repay outstanding debt, with the balance allocated to general corporate purposes. Advertisement The IPO will include a fresh issue of equity shares worth ₹353.4 crore and an offer-for-sale (OFS) of up to 1.27 crore equity shares by promoter and non-promoter shareholders. Among the OFS participants are Investcorp Private Equity Fund II, Healthcare Parent Limited, Edoras Investment Holdings Pte. Ltd., and 360 One Special Opportunities Fund. The company may also consider a pre-IPO placement of up to ₹70.6 crore, which would reduce the size of the fresh issue accordingly. Asia's Largest Dialysis Service Provider Established in 2009, NephroPlus has emerged as Asia's largest dialysis services provider and the fifth-largest globally in terms of the number of treatments performed in FY25, according to a Frost & Sullivan report. As of now, the company operates 447 clinics across 269 cities in 21 Indian states and 4 Union Territories, serving over 33,000 patients annually. NephroPlus commands more than 50 percent revenue market share in India's organised dialysis services market. Advertisement NephroPlus has also made a significant push into international markets. It currently operates 34 clinics in the Philippines, 5 in Nepal, 4 in Uzbekistan, and recently entered Saudi Arabia in a bid to tap the Middle East healthcare market. The company's promoters include Vikram Vuppala, BVP Trust (Bessemer Venture Partners), and Investcorp-affiliated entities. Proceeds to Fuel Domestic Expansion As per the DRHP, NephroPlus will allocate ₹129.1 crore from the fresh issue proceeds towards setting up new dialysis clinics in India, which aligns with its strategy to grow its domestic footprint. An additional ₹136 crore will be used to pre-pay or repay certain existing borrowings, enhancing the company's financial flexibility and improving its balance sheet. Advertisement In FY25, the company reported ₹755.8 crore in revenue from operations and a profit after tax of ₹67 crore, reflecting robust growth amid increasing demand for kidney care services. With chronic kidney disease (CKD) rising as the third fastest-growing cause of death globally, and diabetes and hypertension being its primary drivers, NephroPlus is well-positioned to benefit from secular health trends. ICICI Securities, Ambit Private Limited, IIFL Capital Services, and Nomura Financial Advisory and Securities (India) are acting as Book Running Lead Managers (BRLMs) for the IPO. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions. Advertisement

S&R, Saraf guide IHH's Fortis-Gleneagles hospital management tie-up in evolving Indian healthcare market
S&R, Saraf guide IHH's Fortis-Gleneagles hospital management tie-up in evolving Indian healthcare market

Time of India

time2 hours ago

  • Time of India

S&R, Saraf guide IHH's Fortis-Gleneagles hospital management tie-up in evolving Indian healthcare market

Advt By , ETLegalWorld Join the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. All about ETLegalWorld industry right on your smartphone! Download the ETLegalWorld App and get the Realtime updates and Save your favourite articles. S&R Associates represented Malaysia-headquartered IHH Healthcare Berhad , in the strategic collaboration between its Indian subsidiaries Fortis Healthcare Limited and Gleneagles Healthcare India , pursuant to which Fortis will manage the operations of five hospitals in the Gleneagles India network under an operation and maintenance services agreement. Saraf and Partners advised Fortis on the transaction reflects broader sectoral trends driving India's healthcare M&A activity , which saw deal volumes surge in H1 2025 despite a slight dip in total value. Private players are planning significant bed additions with a capital outlay of approximately INR 32,500 crore over five years, with particular focus on tier-2 and tier-3 city expansion and single-specialty hospitals in oncology, nephrology, and collaboration leverages IHH Healthcare Berhad's global integrated healthcare expertise with Fortis's established Indian market presence, positioning both entities to capitalize on India's expanding healthcare demand. The deal aligns with the domestic hospital sector's leadership in healthcare deal activity, as operators seek operational efficiencies and geographic expansion.S&R Associates' team was led by partners Rajat Sethi and Raya Hazarika, along with associate Stuti Dhundia. Head of competition practice Simran Dhir, partner Akshat Kulshrestha and associates Prerana De, Sehaj Mahajan and Ritik Mohapatra provided competition law advisory. Partner Niti Dixit advised on litigation transaction team led by senior partner Vaibhav Kakkar, partners Sahil Arora and Debarpan Ghosh. Partner Akshayy S Nanda's competition team assisted with regulatory compliance matters.

Rehab to ~25L cover: Find out how insured our athletes are against injuries
Rehab to ~25L cover: Find out how insured our athletes are against injuries

Business Standard

time2 hours ago

  • Business Standard

Rehab to ~25L cover: Find out how insured our athletes are against injuries

A career in sports could be financially rewarding. Medals and accompanying fame also add to the lure, nudging youngsters to take that leap. But there are pitfalls too, as injuries have cut short or reduced the career of many promising as well as established athletes worldwide. For many Indian athletes, especially those from modest backgrounds, a single accident can derail years of hard work and jeopardise their financial future. Medical bills pile up quickly, and the uncertainty of recovery can push families into debt. To provide athletes some cushion against such uncertainties, the government has rolled out several insurance and welfare initiatives. These government-backed schemes not just offer treatment, but provide financial cushioning to athletes, ensuring their focus remains on performance rather than the cost of recovery. Key national-level insurance schemes The Sports Authority of India (SAI) and the Ministry of Youth Affairs and Sports run multiple programmes that cover treatment and insurance for injuries: Pandit Deendayal Upadhyay National Welfare Programme: Provides up to ~10,00,000 for medical treatment to current and retired athletes or their families. This direct financial assistance plays a vital role in post-injury recovery. SAI Medical Insurance Schemes: Covers over 13,000 athletes, coaches and staff. Includes ~500,000 for general medical treatment and an additional ~25,00,000 for accidental death or severe injury. National Centre of Sports Sciences and Research (NCSSR): Offers specialised and subsidised treatment, injury management, and rehabilitation to athletes involved in national programmes, significantly reducing out-of-pocket healthcare costs. Central Athlete Injury Management System (CAIMS): Strengthens medical infrastructure, providing subsidised or free access to treatment facilities, indirectly relieving athletes from financial stress. State initiatives add more protection Several states are bolstering this ecosystem with their own athlete insurance policies: -Haryana offers a medical insurance cover of ~20,00,000 lakh for sportspersons. -Rajasthan's Mukhyamantri Sportsperson Beema Yojana provides ~10,00,000 cover and a ~20,000 monthly pension. What it means for athletes Reduced expenses: Access to government-funded treatment saves lakhs in private medical bills. Focused career building: With medical risks covered, athletes can train without financial anxiety. Caveats and the way forward However, there are gaps. These schemes mainly cover national-level athletes. Those at grassroots or in informal training systems remain uninsured. Awareness is another issue, athletes from rural areas often don't know such benefits exist.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store